MedPath

Digoxin

Generic Name
Digoxin
Brand Names
Digox, Lanoxin
Drug Type
Small Molecule
Chemical Formula
C41H64O14
CAS Number
20830-75-5
Unique Ingredient Identifier
73K4184T59
Background

Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954.

This drug originates from the foxglove plant, also known as the Digitalis plant, studied by William Withering, an English physician and botanist in the 1780s. Prior to this, a Welsh family, historically referred to as the Physicians of Myddvai, formulated drugs from this plant. They were one of the first to prescribe cardiac glycosides, according to ancient literature dating as early as the 1250s.

Indication

Digoxin is indicated in the following conditions: 1) For the treatment of mild to moderate heart failure in adult patients. 2) To increase myocardial contraction in children diagnosed with heart failure. 3) To maintain control ventricular rate in adult patients diagnosed with chronic atrial fibrillation.

In adults with heart failure, when it is clinically possible, digoxin should be administered in conjunction with a diuretic and an angiotensin-converting enzyme (ACE) inhibitor for optimum effects.

Associated Conditions
Myocardial contractility, Ventricular Arrhythmia, Mild to moderate heart failure

Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib

First Posted Date
2025-03-27
Last Posted Date
2025-05-15
Lead Sponsor
AstraZeneca
Target Recruit Count
45
Registration Number
NCT06899061
Locations
🇷🇴

Research Site, Cluj Napoca, Romania

A Research Study of the Effect of Etavopivat on Other Drugs in Healthy Participants

Phase 1
Recruiting
Conditions
Healthy Volunteers Sickle Cell Disease, Thalassemia
Interventions
First Posted Date
2025-02-07
Last Posted Date
2025-03-21
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
29
Registration Number
NCT06813924
Locations
🇺🇸

ICON-Salt Lake City, Salt Lake City, Utah, United States

A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy Adults

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
First Posted Date
2025-01-27
Last Posted Date
2025-04-04
Lead Sponsor
Takeda
Target Recruit Count
78
Registration Number
NCT06793943
Locations
🇺🇸

Celerion, Tempe, Arizona, United States

Influence of HRS9531 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin in Healthy Subjects

Phase 1
Active, not recruiting
Conditions
Type 2 Diabetes
Interventions
First Posted Date
2024-12-09
Last Posted Date
2025-01-07
Lead Sponsor
Fujian Shengdi Pharmaceutical Co., Ltd.
Target Recruit Count
57
Registration Number
NCT06723691
Locations
🇨🇳

The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China

Digoxin Medulloblastoma Study

Phase 2
Recruiting
Conditions
Medulloblastoma
Medulloblastoma, Non-WNT/Non-SHH
Interventions
First Posted Date
2024-11-22
Last Posted Date
2025-04-22
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
23
Registration Number
NCT06701812
Locations
🇺🇸

University of Alabama at Birmingham Children's of Alabama, Birmingham, Alabama, United States

🇺🇸

Children's National Medical Center, Washington, District of Columbia, United States

🇺🇸

Johns Hopkins All Children's, Saint Petersburg, Florida, United States

and more 11 locations

A Clinical Trial to Investigate the Clinical Drug-Drug Interaction of Divarasib With Probe Substrates of P-Glycoprotein and Breast Cancer Resistance Protein in Healthy Participants

Phase 1
Completed
Conditions
Healthy Participants
Interventions
First Posted Date
2024-11-07
Last Posted Date
2025-01-03
Lead Sponsor
Genentech, Inc.
Target Recruit Count
19
Registration Number
NCT06677957
Locations
🇺🇸

Daytona Beach Clinical Rsch Unit, Daytona Beach, Florida, United States

A Study of the Effect of Nemtabrutinib (MK-1026) on the Plasma Levels of Digoxin in Healthy Participants (MK-1026-012)

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2024-10-03
Last Posted Date
2024-10-03
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
24
Registration Number
NCT06625827
Locations
🇺🇸

ICON (Site 0001), Lenexa, Kansas, United States

Digoxin In NASH (CODIN)

Phase 2
Not yet recruiting
Conditions
NASH
NAFLD
MASH - Metabolic Dysfunction-Associated Steatohepatitis
Mash
MASLD
Fatty Liver Disease, Nonalcoholic
MASH With Fibrosis
Fatty Liver Disease
Interventions
Drug: Placebo
First Posted Date
2024-09-19
Last Posted Date
2025-04-13
Lead Sponsor
Yale University
Target Recruit Count
144
Registration Number
NCT06588699
Locations
🇺🇸

Yale New Haven Health, New Haven, Connecticut, United States

🇺🇸

Yale New Haven Hospital, New Haven, Connecticut, United States

A Clinical Study to Assess the Effect of Enlicitide on How the Body Processes Digoxin in Healthy Adult Participants (MK-0616-031)

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2024-09-19
Last Posted Date
2024-11-29
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
24
Registration Number
NCT06597760
Locations
🇺🇸

Celerion ( Site 0001), Lincoln, Nebraska, United States

A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects

Phase 1
Not yet recruiting
Conditions
Healthy Adult Subject
Overweight Subject
Interventions
First Posted Date
2024-09-19
Last Posted Date
2024-09-19
Lead Sponsor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Target Recruit Count
30
Registration Number
NCT06601517
Locations
🇨🇳

Peking University Third Hospital, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath